cyclophosphamide; hematopoietic transplant High-dose busulfan (Bu; 16 mg/kg), given orally, has been a standard component of hematopoietic transplant regimens for over 20 years. [1] [2] [3] [4] [5] At this dose, the hematologic toxicity predominates, mandating stem cell rescue. Other potentially serious side effects include seizures, interstitial pneumonitis (IP), and hepatic veno-occlusive disease (VOD). 6 Historically, the administration of high-dose oral Bu has been spread over 4 days in an every 6-h dosing schedule. The rationale for establishing this dosing scheme was partly practical -a typical dose for a 70-kg patient involves swallowing over 560 tablets -and the concern that exposure to high peak plasma and portal vein concentrations may be associated with certain toxicities, such as seizures and VOD. [6] [7] [8] [9] [10] [11] [12] A parenteral formula became available for human use in 1999 (Busulfex s , ESP Pharma, Edison, NJ, USA). 13 The initial trials of this formulation were designed to duplicate the experience with oral Bu and, therefore, used an every 6-h dosing schedule. 7 The results showed equivalence in terms of toxicity and efficacy between the oral and parenteral forms.
As experience with the parenteral formulation has grown, [14] [15] [16] [17] [18] investigators have begun to study daily Bu dosing schemes in combination with fludarabine 12, 19, 20 and cyclophosphamide (Cy). 21 In general, these investigators concluded that toxicity and engraftment profiles were similar to the standard Bu i.v. every 6 h/Cy regimen, although several cases of hepatic toxicity were observed by Fernandez et al. 21 The authors suggested further evaluation. Since a daily dosing scheme exposes the patient to peak levels that are approximately three to four times higher than with every 6 h dosing, both toxicity (VOD, IP, seizures) and antileukemic efficacy may be affected. 7, [21] [22] [23] [24] To study this question further, a single institution trial of three different groups undergoing allogeneic hematopoietic transplant was performed. The experimental group (group A) consisted of 20 patients prospectively enrolled in a clinical trial of Bu i.v. once daily. The control groups consisted of two sets of patients who received Bu by alternate methods. Group B was a concurrent control group of 11 patients who received Bu i.v. every 6 h. Group C was a consecutive series of 25 patients, analyzed retrospectively, who received Bu p.o. every 6 h. All groups were treated at Baylor University Medical Center, Dallas, TX, USA, between 2000 and 2004. All patients in group A underwent pharmacokinetic (PK) monitoring as did 10/11 patients in group B and 13/25 patients in group C. All patients participated in clinical and laboratory data collection on IRB-approved protocols.
Patients and methods

Patient enrollment
All patients considered appropriate to receive a Bu/Cy conditioning regimen by the attending physician staff were considered eligible for enrollment in the prospective study. Eligible diseases included any myeloid or lymphoid leukemia, myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), or other hematological disorders (Table 1) . At least 6 weeks had to have elapsed since most recent prior cytotoxic therapy. An HLA-matched sibling or matched unrelated donor was required. HLA match grade was determined by DNAsequencing at A, B, C, DRB1, and DQB1 loci. The match grade had to be better than or equal to a 2 allele-level mismatch or a single 'antigen' level mismatch. Other inclusion criteria included age p65; normal pulmonary, renal, and hepatic function tests; the ability to comprehend informed consent; and Karnofsky performance status (KPS) X70%. doses). All Bu doses were followed by Cy 60 mg/kg i.v. once daily for 2 days for groups A, B, and C. The time intervals between the final Bu dose and the first Cy dose were 27 h for group A and 18 h for groups B and C. The Busulfex s infusions were admixed per package insert guidelines to a final concentration of 0.54 mg/ml. They were given as a 3-h infusion for group A and a 2-h infusion for group B. 20, 25 The chemotherapy doses were based on actual body weight (ABW) or ideal body weight (IBW), whichever was less; however, if the difference between ABW and IBW was greater than 50 pounds, then IBW þ 10% was used for dosage calculations. All patients received seizure prophylaxis with phenytoin at a dose of 1 g p.o. (load) on day 1 prior to the first dose of Bu, followed by 300 mg p.o. daily for 4 days. Serum phenytoin levels were not monitored.
Conditioning regimen
Graft-versus-host disease prophylaxis
All patients received a standard graft-versus-host disease (GVHD) prophylaxis regimen consisting of i.v. tacrolimus starting on day À1 of transplant with i.v. 'mini' methotrexate (5 mg/m 2 ) given on days þ 1, þ 3, and þ 6. 26 Five patients in group B also received antithymocyte globulin (ATG) (Thymoglobulint) 4.5 mg/kg total dose as part of their conditioning regimen to further prevent rejection or acute GVHD (AGVHD). 20 Methotrexate prophylaxis was omitted in one patient with relapsed ALL (second allogeneic transplant). Granulocyte colony-stimulating Daily busulfan reduces toxicity K Mamlouk et al factor filgrastim (G-CSF) was given to all patients starting on day þ 8 post transplant until engraftment was achieved.
Toxicity and GVHD grading
All patients in the prospective trial (group A) were graded weekly for clinical end points by the principal investigator. Concurrent case controls (group B) and historical controls (group C) were graded by the attending physician and were reviewed by the authors. Toxicity grading was according to the National Institutes of Health (NIH) common toxicity grading scheme (CTCAE v. 3.0) http://ctep.cancer.gov. Clinical staging and grading of GVHD was according to Thomas et al.
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Definitions Engraftment was defined as the first day of 3 consecutive days for which the absolute neutrophil count (ANC) was X0.5 Â 10 9 /l. Failure to engraft by day þ 30 was considered as an engraftment failure. Seizures were defined as any witnessed tonic-clonic motor activity with or without incontinence or alterations in consciousness. Hepatic VOD was defined according to the clinical criteria as devised by McDonald et al. 28 IP was defined as any idiopathic pulmonary infiltrate occurring with nondiagnostic bronchoalveolar lavage, blood, or respiratory cultures/studies. Relapse was defined according to standard definitions of the International Blood and Marrow Transplant Registry (IBMTR). 29 
Pharmacokinetic sampling and analysis
Group A patients had 7 PK blood samples drawn immediately at the end of the first 3-h infusion (3-h time point, or peak) and at 3.25, 3.5, 4, 6, 12, and 14 h from the start of the infusion. Samples were drawn from a central venous catheter using a lumen, separate from the one used for drug administration. Precise draw times were recorded.
Group B patient samples were drawn immediately at the end of the first 2-h infusion (2-h time point, peak level) and at 2.25, 2.5, 3, 4, 5, and 6 h after the start of the infusion.
Group C patient samples were drawn 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 6 h after the first oral administration.
All samples were collected on ice in heparinized (Na þ or Li þ heparin) tubes, then centrifuged within 1 h. The plasma was harvested into cryovial storage tubes, and was sent in a frozen state packaged with dry ice, and shipped by overnight courier to a validated reference lab for analysis to determine plasma Bu concentration. The results were available within 24 h.
All concentration-time plasma Bu data were analyzed using one compartment first-order elimination based on day 1 plasma drug levels using the WinNonlint PK software program (Pharsight, Mountain View, CA, USA) 30 for groups A and B. Group C AUC analysis was based on noncompartmental elimination using Lagran PK software. 31 If necessary, adjustments were made to the third and fourth doses for group A and for the last 10 doses for groups B and C based on the results of the AUC analysis. The adjustments were made in order to achieve an average targeted therapeutic range of 3600-6000 mmol/min for group A patients and 900-1500 mmol/min for group B patients.
For group C patients, the adjusted dose for the analyzed patients was determined based on the concentration steady state (Css), which is a ratio of Bu AUC over the dosing interval to the time between doses (6 h). 32 This concentration can be targeted differently based on specific diseases, that is, desired CML Css higher than 900 ng/ml and converted to an AUC 41315 mmol/min, and for all other hematological diseases 600-900 ng/ml which correlate to an AUC 877-1315 mmol/min in general. This range has been suggested to decrease the incidence of hepatic VOD and GVHD and to maximize survival by decreasing relapse post transplant in several diseases, including CML and MDS. 14, 22, 32, 33 For patients requiring dosage adjustments in group A, dosages were calculated to achieve a dose within the target range based on the linear properties of the drug while taking into account the AUC achieved with the first 2 doses of the drug. The following formula was used to determine the adjusted dose: desired target AUC ðfor remaining dosesÞ Target area under the curve for both group B and group C varied based on the disease state or physician discretion. Minimum AUC was 900 mmol/min. The new adjusted dose gave the therapeutic average AUC.
Statistical methods
Descriptive statistics were summarized as percentage or as median and range when appropriate. Comparisons between groups were analyzed using the two-tailed Fisher's exact test for 2 Â 2 tables and the two-tailed Fisher-FreemanHalton test for larger tables. Continuous data were analyzed using nonparametric techniques, which included the Kruskall-Wallis analysis of variance procedure and the Mann-Whitney-Wilcoxon procedures for pairwise comparisons. Bonferroni procedure was used to adjust P-values
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Results
Patients and disease characteristics
Patient demographics and disease characteristics are summarized in Table 1 . The median age was 48 years (range, 25-65 years) in group A, 37 years (range, 18-52 years) in group B, and 39 years (range, 20-59 years) in group C. Patients in group A were significantly older than patients in group C (P ¼ 0.0238). There was no difference in sex distribution among groups.
Median time from diagnosis to transplant was 5 months in group A, 4 months in group B, and 6 months in group C. Differences among the groups were not significant.
The predominant diagnoses in groups A and B were AML and MDS, respectively, while most of the patients in group C were diagnosed with CML in first chronic phase.
All patients in group C and 85% in group A had HLAidentical sibling donors while 82% of the donors used in group B were unrelated.
Most of the patients analyzed in all groups were recipients of their first transplant.
Engraftment, toxicity, transplant-related mortality, and relapse Table 2 provides a summary of the time of engraftment, regimen-related toxicity, relapse, and transplant-related mortality within the first 100 days post-transplant All evaluable patients achieved engraftment. One patient in group C died of bacterial infection after 22 days post transplant before the engraftment could be evaluated. The median time to neutrophil engraftment after transplantation was 12 days (range, 11-17 days) in group A, 14 days (range, 12-18 days) in group B, and 13 days (range, 10-26 days) in Group C.
Differences in the incidence of VOD across groups are not significant. One patient (9%) in group B and 2 patients (8%) in group C suffered VOD within 100 days post transplant. One patient (5%) in group A, who completed the 100-day analysis, developed clinical signs and symptoms suggestive of VOD, 28 although no liver biopsy was performed. These clinical and laboratory abnormalities reversed uneventfully. One other patient in group A had features consistent with VOD by day þ 13, but an unequivocal diagnosis of VOD could not be established given concurrent problems of Candida septicemia and relapse of acute myelogenous leukemia.
The 100-day mortality was comparable across the three groups. One group A patient died (relapse and sepsis), two group B patients died (one of VOD, the other IP), and four group C patients died (fungal infection, intracranial hemorrhage, bacterial infection, and multiple-organ failure).
The incidence of IP was not significantly different between groups. In group A, two patients (10%) had pneumonitis and required intubation. One reversed completely in 7 days with no alternative diagnosis by bronchoalveolar lavage (open lung biopsy not performed). The other patient (mentioned above) had concurrent problems of Candida septicemia and relapse of acute myelogenous leukemia.
No seizures were recorded in any of the patients during drug administration with the exception of one patient in group B.
Relapse was comparable across groups; although, as mentioned, their diagnoses varied. One patient in group A, with a diagnosis of mastocytosis, relapsed. One patient in group B, with MDS refractory anemia with excess blasts in transformation, relapsed. In Group C, two patients transplanted with AML and one patient with MDS refractory anemia with excess blast in transformation relapsed. Table 2 shows that the rates of grade III-IV AGVHD were 5% for group A, 0% for group B, and 36% for group C patients. The overall incidence of aGVHD (grade I-IV) was 47% in group A, 36% in group B, and 48% in group C (data not shown). Comparisons among the groups showed that both group A and group B experienced a significantly lower incidence of severe aGVHD than group C, respectively (5 vs 36%, P ¼ 0.0271 and 0 vs 36%, P ¼ 0.0341).
GVHD
PK analysis
Bu PK parameters were calculated from the data obtained from blood samples of 20 patients in group A, 10 patients in group B, and 13 patients in group C.
The clearance (CL) and Css were calculated using the AUC. PK parameters for the analyzed patients are summarized in Table 3 . The mean CLs of groups A, B, and C were 3.34, 3.74, and 2.97 ml/min/kg, respectively. The mean and median daily AUCs were, respectively, for group A: 4017 and 4071 mmol/min (range, 2502-5038 mmol/min); for group B: 1024 and 994 mmol/min (range, 675-1313 mmol/ min); and for group C: 1394.4 and 1305.2 mmol/min (range, 1027-1827 mmol/min). Table 2 Engraftment, mortality, regimen-related toxicity, relapse, and Grade III-IV acute graft-versus-host disease
Median time to ANC4 500 days, n (range)
12 (11-17) 14 (12-18) 13 (10-26) 0.01 a 100-day mortality, n (%) 1 (5%) 2 (18%)
a Group A vs group B (P ¼ 0.0108). One patient in group C died before engraftment could be evaluated. b Group A patients experienced a significantly lower incidence of severe acute graft-versus-host disease than group. B patients (P ¼ 0.0271). A patient with syngeneic donor in group A was excluded from the analysis.
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Of the 20 patients in group A, no one exceeded the targeted Bu concentration. Four of the 20 patients (20%) had an AUC lower than the desired concentration, resulting in dosage adjustments for the third and fourth doses. Of these four patients who required dosage adjustments, two were more than 50 pounds over their IBW and were dosed using our program-specific formula for adjusted body weight (IBW þ 10%). In total, 11 of the 20 patients (55%) were dosed on either their ABW or IBW and did not need dosage adjustment. All of these 11 patients were within 20% of their IBW or weighed less than their IBW. In the remaining nine patients, the ABW was greater than 20% of their IBW. Five of these nine patients were dosed using IBW þ 10%. Four of these nine patients (44%) fell below the therapeutic range and required dosage adjustments. This result suggests that patients who weigh pIBW þ 20% are not likely to require a dose adjustment (P ¼ 0.026).
Discussion
Based on the work of others, the advantages of parenteral Bu (Busulfex s ) appear to be ease of administration, consistent bioavailability, and reproducibility of AUC, the absence of a first-pass hepatic metabolism and exposure, and a dose-dependent antileukemic effect in diseases such as MDS 33 and chronic myelogenous leukemia. 36 High doses of oral Bu and high plasma concentrations are correlated with the incidence of hepatic VOD. [6] [7] [8] [9] [10] [11] Reasonable concerns have been raised about the potential toxicity of daily i.v. Bu for which peak levels are approximately three to four times higher than with a 6-h scheme. In addition, theoretical concerns have been raised about the additive depletion of hepatic glutathione reserves by both Bu and Cy leading to further hepatic toxicity. 37, 38 The results of this study do not support these concerns. The incidence of VOD, indeed any hepatotoxicity, in this study was only 5% in group A, a result comparable to other recent studies which used once daily i.v. Bu in conjunction with other agents such as fludarabine. 12, 20 The cost of parenteral Bu for a hypothetical 70-kg patient is approximately $4300 (AWP). This compares to a cost of approximately $500 for the oral formulation. The cost associated with PK testing, subsequent dose adjustments and re-testing are estimated to range between $1000 and $2000. The greater costs of the parenteral formulation have been justified by others in terms of greater patient safety, patient comfort, and, ultimately, greater efficacy due to less interpatient variation, especially with young patients who are known to metabolize the drug faster than adults leading to low levels. 34, 39 PK measurement of plasma Bu levels is now routinely available and has been a valuable adjunct for patients receiving the oral formulation for which there can be a large (up to three-fold) interpatient variation due to differences in absorption and metabolism. 40 Young adults and children are especially likely to have low levels with the oral form. 39 It has been suggested that PK measurement may not be needed with the parenteral formulation due to the absence of hepatic first-pass metabolism and the absorption problem. 41 The results of this investigation seem to support this point of view.
The data found from group A demonstrates predictable PK parameters. The target systemic exposure dose of 900-1500 mmol/min per dose in intermittent dosing (6 h) would be equivalent to daily systemic exposure dose of 3600-6000 mmol/min. The median number in group A (once daily) fell within that range (4071 mmol/min) and below the level associated with increased risk of toxicity. The mean half-life of 2.88 h and median 2.85 h in group A (once daily) is not significantly different than the median of 2.9 h previously reported using every 6 h dosing. 14 Data from patients whose body mass were no greater than 20% of their ideal showed that the dosing formula resulted in plasma PK values in the desired range (3600-6000 mmol/min) for 11/16 patients. This suggests that PK measurement and dose tailoring may be unnecessary in this group of patients. 41 In the remaining nine patients, whose body mass was in excess of IBW þ 20%, for four of those patients, the data showed that the dosing formula consistently resulted in low levels, requiring a dose adjustment. For this group, an alternate formula (IBW þ 40% of FBW) may be considered. 42 We observed a statistically significant decrease in the incidence of grade III-IV AGVHD in those patients receiving Bu i.v. once daily, compared with the group receiving Bu p.o. every 6 h. This is all more significant since the Bu i.v. once daily group contained several patients transplanted with matched unrelated donors in whom the GVHD risk is known to be elevated. The reasons for this decrease are speculative but may include a reduction in gut toxicity with once daily vs every 6 h dosing; patients in group C had an AUC approximately 25% higher than patients in groups A and B. Release of inflammatory cytokines, such as TNF-a, from damaged intestinal epithelium, has been shown in animal models to increase the rate of aGVHD. 43 It is to be noted that aGVHD was a secondary end point of this study and that comparison groups were not stratified for aGVHD risk. For example, several of the patients in group A received ATG during the conditioning regimen, and an excess of patients in group C had a diagnosis of CML. These factors may well have influenced the overall incidence and severity of aGVHD. a The AUC was normalized (group A) or converted from Css (ng/ml) to AUC (group C) to allow for comparisons. b Group A vs group C (P-value ¼ 0.0015); group B vs group C (P-value ¼ 0.0195).
For these reasons, the observed effect remains to be confirmed by prospective studies. The observed effect remains to be confirmed by prospective studies.
In conclusion, parenteral Bu (Busulfex s ), when used in a daily schedule (3.2 mg/kg i.v. once daily for 4 days) in conjunction with Cy (60 mg/kg i.v. once daily for 2 days), appears to offer a safe, convenient, and consistent allogeneic transplant treatment regimen suitable in selected patients for outpatient administration without PK measurement.
